DeepNewz Markets

Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech

Apr 25, 2024, 12:25 AM

Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.

View original story

Markets

FDA approval for Xaira's RFdiffusion tech by April 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

Official FDA announcements and press releases

Marc Tessier-Lavigne as Xaira CEO through 2026?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

Company press releases and major business news outlets

Xaira Additional Funding of Over $500M by 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Yes • 50%

No • 50%

SEC filings, press releases from Xaira, or major financial news outlets

Xaira announces over $500M in new funding by end of 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

Company financial disclosures and news outlets

Xaira FDA Approval for RFdiffusion Technology by 2026

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Yes • 50%

No • 50%

FDA official announcements or reliable healthcare news sources

Xaira forms major pharma partnership by mid-2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Yes • 50%

No • 50%

Press releases from Xaira and potential partners

Xaira IPO by end of 2026?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Yes • 50%

No • 50%

SEC filings and major financial news outlets

Xaira RFdiffusion Clinical Trials Initiation by 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Yes • 50%

No • 50%

Press releases from Xaira or coverage in biotechnology industry publications

Xaira secures patent for RFdiffusion technology by end of 2024?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

US Patent and Trademark Office records

Xaira to launch a marketable RFdiffusion product by 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

Company announcements or major biotech industry publications.

Xaira to partner with a top 10 pharmaceutical company by 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

Company press releases or major pharmaceutical industry reporting.

Xaira to secure over $500 million in next funding round by 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

No • 50%

Yes • 50%

SEC filings, company press releases, or major financial news outlets.

First Therapeutic Area Targeted by Xaira's RFdiffusion Technology

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Infectious Diseases • 25%

Oncology • 25%

Neurodegenerative Diseases • 25%

Cardiovascular Diseases • 25%

Company announcements or major biotech industry publications.

Leading Venture Capital Firm in Xaira's Next Funding Round

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

F-Prime • 13%

Arch • 13%

Sequoia • 13%

NEA • 13%

Foresite • 13%

Two Sigma • 13%

Lightspeed • 13%

Lux • 13%

SEC filings, company press releases, or major financial news outlets.

Major scientific breakthrough by Xaira by 2029

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Breakthrough in a different field • 34%

Breakthrough in biopharmaceuticals • 33%

No breakthrough • 33%

Scientific journals, company press releases, and major science news outlets

Market valuation of Xaira one year post-IPO

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Above $20 billion • 25%

Between $10 billion and $20 billion • 25%

Between $5 billion and $10 billion • 25%

Below $5 billion • 25%

Stock market data and financial news analysis

Number of Major Pharma Partnerships for Xaira by 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

More than 5 partnerships • 25%

0 partnerships • 25%

3-5 partnerships • 25%

1-2 partnerships • 25%

Press releases from Xaira or major pharmaceutical companies, business news outlets

Number of new drug candidates from Xaira by 2026

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

4-5 new candidates • 25%

More than 5 new candidates • 25%

0-1 new candidates • 25%

2-3 new candidates • 25%

Company R&D updates, press releases, and healthcare publications

Outcome of Xaira's first clinical trial by 2026

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Inconclusive results • 25%

Highly successful • 25%

Failed • 25%

Partially successful • 25%

Clinical trial results published on clinicaltrials.gov or similar platforms

Outcomes of Xaira's First Major RFdiffusion Publication by 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Inconclusive results • 34%

Breakthrough findings • 33%

Incremental findings • 33%

Scientific publications or major scientific journals

Top Investor in Xaira's Next Funding Round

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

F-Prime • 14%

Arch • 14%

Foresite • 14%

NEA • 14%

Sequoia • 14%

Lux • 14%

Lightspeed • 14%

Two Sigma • 2%

Press releases from Xaira, SEC filings, or financial news coverage

Will Marc Tessier-Lavigne remain CEO of Xaira by end of 2025?

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Remains CEO • 50%

Steps down • 50%

Company press releases or major business news outlets.

Xaira's market position by end of 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

Leader in biotech market • 25%

Struggles to scale • 25%

Top 5 in biotech market • 25%

Moderately successful • 25%

Market analysis reports and company financial statements

Xaira's next major innovation type by end of 2025

Xaira•David Baker•Arch•Foresite•NEA•Sequoia•Lux•Lightspeed•Two Sigma

Resolution / Starting Odds

None • 20%

AI-driven diagnostic tool • 20%

New drug delivery system • 20%

Genetic editing technology • 20%

Advanced biopharmaceutical therapy • 20%

Xaira press releases and technology disclosures

Looking for markets...